Status:
UNKNOWN
Clinical Validation of the Prognostic Value of the PrTS on Prostate Cancer Patients
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Collaborating Sponsors:
Prostatype Genomics AB
GloriousMed Clinical Laboratory (Shanghai) Co., Ltd.
Conditions:
Prostate Cancer
Eligibility:
MALE
50-100 years
Brief Summary
Prostate Cancer is the most common type of cancer among men in many countries. However current clinical tools have limited prediction accuracy to choose the optimal treatment for the individual patien...
Eligibility Criteria
Inclusion
- Non-metastatic prostate adenocarcinoma confirmed by histopathology after taking core needle biopsy
- Regular visits, treatment and laboratory tests were conducted in the past
- There is biopsy materials at the time of diagnosis (without staining FFPE)
- The total area of tumor tissue shall be 25-30 mm2, and the proportion of tumor cells after tumor cell enrichment is at least 50%
- Complete records of relevant clinical follow-up information
Exclusion
- Biopsy tissue is not available, or FFPE does not meet the screening requirements of study samples
- Relevent clinical parameters of the patients are not available
- Treatment methods are not available
- Age of diagnosis \< 50 years
- Age of diagnosis \> 100 years
- Total tumor length \< 2 mm
- The patient died of an accident, homicide or suicide
Key Trial Info
Start Date :
September 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05248282
Start Date
September 1 2021
End Date
December 31 2022
Last Update
February 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University
Nanjing, Jiangsu, China, 210000